Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allogene MSCs Transplantation Chronic Liver Diseases Patients Peripheral Vein

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

allogene MSCs transplantation chronic liver diseases peripheral vein

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allogene MSCs transplantation

Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.

No interventions assigned to this group

control

only medical treatments were performed in patients with chronic liver diseases.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
2. age: 15-65 years old.

Exclusion Criteria

1. pregnant women and women in lactation.
2. other systems and organs disfunction
3. space-occupying lesion were found in liver.
4. concurrent infection with HIV and other immunodeficiency diseases.
5. DIC and active bleeding were confirmed.

Minimum Eligible Age

15 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

3rd Affiliated Hospital of Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Liang Peng, Dr.

Role: primary

Jing Liu, Master

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SunYat-sen U 11-5-1

Identifier Type: -

Identifier Source: org_study_id